Novel SL Target Inhibitor
AML, DLBCL, HR-deficient solid tumors
Early DiscoveryActive
Key Facts
Indication
AML, DLBCL, HR-deficient solid tumors
Phase
Early Discovery
Status
Active
Company
About Evariste Technologies
Evariste Technologies is a private, preclinical-stage biotech applying advanced mathematical modeling and machine learning to discover and develop small molecule drugs for synthetic lethal oncology indications. Its core asset is the Frobenius AI platform, which integrates multi-omic data for novel target identification and employs machine learning for efficient small molecule design and optimization. The company has built an early pipeline featuring programs against targets like PKMYT1 and VRK1, and is led by a team with expertise in drug discovery, AI, and mathematics.
View full company profile